Organovo Holdings Inc
ONVO
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.69M
Close$
$0.16
92.3% downside
Current Fair Value
92.3% downsideOvervalued by 92.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.69 Million |
|---|---|
| Enterprise Value | $9.33 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.35 |
| Beta | 1.13 |
| Outstanding Shares | 5,239,462 |
Return
| Return on Equity | 525.92% |
|---|---|
| Return on Assets | -320.72% |
| Return on Invested Capital | -729.02% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | 0.05 |
| Price to Sales | - |
| Price to Book Ratio | -2.04 |
| Enterprise Value to Revenue | 83.34 |
| Enterprise Value to EBIT | -0.66 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | -0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
February 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Organovo Holdings Inc
15 employees
CEO: Keith Murphy VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicolo...